ZUBSOLV® is indicated for the maintenance treatment of opioid use disorder (OUD) and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. The drug is based on Orexo´s sublingual drug delivery platform and is available in six dosage strengths.
Orexo commercializes ZUBSOLV® in the US. In the EU, ZUBSOLV® is commercialized by Orexo´s partner Accord Healthcare. Rights to other markets are owned by Orexo.
Abstral is indicated for treatment of breakthrough cancer pain, developed based on the company´s sublingual drug delivery platform.
Kyowa Kirin provides commercialization of Abstral® outside the US and EU, where patents have expired.
Edluar is indicated for the treatment of short-term insomnia, developed based on the company´s sublingual drug delivery platform.
Mylan provides commercialization of Edluar® worldwide outside the US.
Digital therapy for opioid use disorder
MODIA® is a 6-month therapy based on cognitive behavioral therapy techniques and should be used as part of a supervised medication-assisted treatment program for OUD. The therapy helps users develop a customized relapse prevention plan based on the responses collected from the exercises throughout the program.
Developed in collaboration with GAIA AG
Evidence based digital therapy for alcohol management
Vorvida® is a 6-month online program that can break negative thought patterns and responses to change behavior around alcohol. The therapy is developed in consultation with psychologists, physicians and patients and is based on cognitive behavioural therapy techniques. The effectiveness of vorvida® is evaluated in randomized clinical trial, including approximately 600 patients.1
Developed by GAIA AG
Evidence based digital therapy for depression
Deprexis® is a 3-month online program that can help people create more positive thoughts and behaviors. The therapy is developed in consultation with psychologists, physicians and patients and is based on cognitive behavioural therapy techniques. Its effectiveness has been evaluated and published in 12 randomized clinical trials (RCTs) including more than 2,800 patients. Deprexis® can be used as a standalone treatment or alongside traditional pharmaceuticals.2
Developed by GAIA AG
1 Jördis M. Zill, Eva Christalle, Björn Meyer, Martin Härter, and Jörg Dirmaier The Effectiveness of an Internet Intervention Aimed at Reducing Alcohol Consumption in Adults: Results of a Randomized Controlled Trial (Vorvida) Dtsch Arztebl Int 2019; 116: 127–33. DOI: 10.3238/arztebl.2019.0127
2 Twomey et al. (2020), Zwerenz et al. (2017), Berger et al. (2018), Beevers et al. (2017), Klein et al. (2016), Meyer et al. (2015), Moritz et al. (2012), Berger et al. (2011), Meyer et al. (2009), Bücker et al. (2018), Fischer et al. (2015), Schröder et al. (2014)